Combining Yttrium 90–Labeled Ibritumomab Tiuxetan with High-Dose Chemotherapy and Stem Cell Support in Patients with Relapsed Non-Hodgkin's Lymphoma

This publication has 20 references indexed in Scilit:

• Zevalin dose-escalation followed by high-dose beam and autotransplant in cd20+ relapsed or refractory non-hodgkin lymphoma (NHL)
  Transplantation and Cellular Therapy, 2004
• The city of hope experience with novel transplant regimens that incorporate standard and escalated dose 90YTTRIUM ibritumomab tiuxetan (90Y-Zevalin®) radioimmunotherapy (RIT) for autologous stem cell transplantation (ASCT) in patients with B-cell non-Hodgkin’s lymphoma (NHL): targeted intensification without increased toxicity and elimination of total body irradiation (TBI)
  Transplantation and Cellular Therapy, 2004
• High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin’s Lymphoma: Results From the Randomized European CUP Trial
  Journal of Clinical Oncology, 2003
• Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma
  Blood, 2003
• Intensive therapies in follicular non-Hodgkin lymphomas
  Blood, 2002
• Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience
  Blood, 2000
• Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.
  Journal of Clinical Oncology, 1996
• Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
  New England Journal of Medicine, 1995
• BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
  Journal of Clinical Oncology, 1995
• Radioimmunotherapy of B-Cell Lymphoma with [¹³¹I]Anti-B1 (Anti-CD20) Antibody
  New England Journal of Medicine, 1993